ES2170807T3 - Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria. - Google Patents

Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.

Info

Publication number
ES2170807T3
ES2170807T3 ES95932999T ES95932999T ES2170807T3 ES 2170807 T3 ES2170807 T3 ES 2170807T3 ES 95932999 T ES95932999 T ES 95932999T ES 95932999 T ES95932999 T ES 95932999T ES 2170807 T3 ES2170807 T3 ES 2170807T3
Authority
ES
Spain
Prior art keywords
prostaglandin
prevention
treatment
pct
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932999T
Other languages
English (en)
Inventor
Johan Stjernschantz
Bahram Resul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synphora AB
Original Assignee
Synphora AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synphora AB filed Critical Synphora AB
Application granted granted Critical
Publication of ES2170807T3 publication Critical patent/ES2170807T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Prostheses (AREA)

Abstract

METODO PARA TRATAR O PREVENIR LAS CATARATAS SECUNDARIAS QUE SUPONE LA PUESTA EN CONTACTO DE LA SUPERFICIE DEL OJO CON UNA CANTIDAD EFECTIVA DE UNA PROSTAGLANDINA TERAPEUTICAMENTE ACTIVA Y ACEPTABLE FISIOLOGICAMENTE DEL TIPO A O J, ESPECIALMENTE PGA{SUB,2} O PGJ{SUB,2} O UN ANALOGO O DERIVADO DE LO ANTERIOR.
ES95932999T 1994-09-21 1995-09-19 Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria. Expired - Lifetime ES2170807T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403160A SE9403160D0 (sv) 1994-09-21 1994-09-21 Method and means for prevention and treatment of secondary cataract

Publications (1)

Publication Number Publication Date
ES2170807T3 true ES2170807T3 (es) 2002-08-16

Family

ID=20395311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932999T Expired - Lifetime ES2170807T3 (es) 1994-09-21 1995-09-19 Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.

Country Status (10)

Country Link
US (1) US5760075A (es)
EP (1) EP0782447B1 (es)
JP (1) JPH10505860A (es)
AT (1) ATE213634T1 (es)
AU (1) AU704459B2 (es)
CA (1) CA2200481C (es)
DE (1) DE69525631T2 (es)
ES (1) ES2170807T3 (es)
SE (1) SE9403160D0 (es)
WO (1) WO1996009054A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8656098A (en) * 1997-07-23 1999-02-16 Brigham And Women's Hospital Lens epithelial cell derived growth factor
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US6533769B2 (en) * 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery
JP5682991B2 (ja) * 2004-10-01 2015-03-11 ラムズコア， インコーポレイテッド 便利に移植可能な徐放性薬物処方物
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPH0643313B2 (ja) * 1986-03-13 1994-06-08 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
TW224942B (es) * 1990-04-04 1994-06-11 Adka Ueno Kk

Also Published As

Publication number Publication date
AU704459B2 (en) 1999-04-22
CA2200481C (en) 2002-09-10
ATE213634T1 (de) 2002-03-15
DE69525631D1 (de) 2002-04-04
SE9403160D0 (sv) 1994-09-21
US5760075A (en) 1998-06-02
EP0782447B1 (en) 2002-02-27
JPH10505860A (ja) 1998-06-09
CA2200481A1 (en) 1996-03-28
WO1996009054A1 (en) 1996-03-28
AU3581695A (en) 1996-04-09
EP0782447A1 (en) 1997-07-09
DE69525631T2 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
AU3402295A (en) Methods and means for drug administration
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
EA200300560A1 (ru) Улучшенный способ лечения
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
DE69431601T2 (de) Neue verwendung von dexmedetomidin
EP1110554A4 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
BR9509975A (pt) Formulação farmacêutica
BG98827A (en) Pharmaceutical composition and method for its preparation
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE69100171T2 (de) Synergistische Kombination zur ophthalmischen Verwendung.
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
SE9404438D0 (sv) New process
MX9400288A (es) Procedimiento para la preparacion de un medicamento util como radiorestaurador.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 782447

Country of ref document: ES